Akari Therapeutics Analyst Ratings
Akari Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/05/2022 | 178.45% | HC Wainwright & Co. | → $1.5 | Initiates Coverage On | → Buy |
| 11/01/2022 | 642.53% | Alliance Global Partners | → $4 | Initiates Coverage On | → Buy |
| 03/13/2020 | 828.16% | B. Riley Securities | $7 → $5 | Maintains | Buy |
| 03/29/2018 | 1385.06% | Canaccord Genuity | $15 → $8 | Maintains | Buy |
| 02/08/2018 | 456.9% | B. Riley Securities | → $3 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 12/05/2022 | 178.45% | HC Wainwright & Co. | → 1.5 美元 | 启动覆盖范围开启 | → 购买 |
| 11/01/2022 | 642.53% | 联盟全球合作伙伴 | → 4 美元 | 启动覆盖范围开启 | → 购买 |
| 03/13/2020 | 828.16% | B. 莱利证券 | 7 美元 → 5 美元 | 维持 | 购买 |
| 03/29/2018 | 1385.06% | Canaccord Genu | 15 美元 → 8 美元 | 维持 | 购买 |
| 02/08/2018 | 456.9% | B. 莱利证券 | → 3 美元 | 启动覆盖范围开启 | → 中立 |
What is the target price for Akari Therapeutics (AKTX)?
Akari Therapeutics（AKTX）的目标价格是多少？
The latest price target for Akari Therapeutics (NASDAQ: AKTX) was reported by HC Wainwright & Co. on December 5, 2022. The analyst firm set a price target for $1.50 expecting AKTX to rise to within 12 months (a possible 178.45% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年12月5日公布了Akari Therapeutics（纳斯达克股票代码：AKTX）的最新目标股价。该分析公司将目标股价设定为1.50美元，预计AKTX将在12个月内上涨至1.50美元（可能上涨178.45％）。去年有两家分析公司公布了评级。
What is the most recent analyst rating for Akari Therapeutics (AKTX)?
Akari Therapeutics（AKTX）的最新分析师评级是多少？
The latest analyst rating for Akari Therapeutics (NASDAQ: AKTX) was provided by HC Wainwright & Co., and Akari Therapeutics initiated their buy rating.
Akari Therapeutics（纳斯达克股票代码：AKTX）的最新分析师评级由HC Wainwright & Co. 提供，Akari Therapeutics启动了买入评级。
When is the next analyst rating going to be posted or updated for Akari Therapeutics (AKTX)?
Akari Therapeutics（AKTX）的下一个分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akari Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akari Therapeutics was filed on December 5, 2022 so you should expect the next rating to be made available sometime around December 5, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Akari Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Akari Therapeutics的最后一次评级是在2022年12月5日发布的，因此您应该预计下一个评级将在2023年12月5日左右公布。
Is the Analyst Rating Akari Therapeutics (AKTX) correct?
分析师评级Akari Therapeutics（AKTX）是否正确？
While ratings are subjective and will change, the latest Akari Therapeutics (AKTX) rating was a initiated with a price target of $0.00 to $1.50. The current price Akari Therapeutics (AKTX) is trading at is $0.54, which is within the analyst's predicted range.
尽管评级是主观的，而且将发生变化，但最新的Akari Therapeutics（AKTX）评级是启动的，目标股价为0.00美元至1.50美元。Akari Therapeutics（AKTX）目前的交易价格为0.54美元，在分析师的预测区间内。